Partnerships & Acquisitions

Pharmaceutical Partnerships

We partner with organisations to maximise the value of late-stage and ready-to-market pharmaceutical products and assets through licensing and acquisition opportunities.

Our Approach to Partnership

Our Partnerships

Partnership Opportunities

We focus on partnership opportunities involving pharmaceutical products and assets that align with our expertise and strategic objectives.

Licensing Opportunities

Late-stage and commercial pharmaceutical licensing opportunities across the UK, Ireland, the Nordics, and wider European markets.

Learn More

Strategic Acquisitions

We evaluate acquisition opportunities involving companies, marketed products, product portfolios and pharmaceutical assets that strengthen our business and support long-term growth.

Learn More

Why Partner with Galen

Our partnership approach combines pharmaceutical expertise, operational excellence and a commitment to delivering mutually beneficial outcomes.

Commercial Expertise

Established experience launching and growing pharmaceutical products across the UK, Ireland and European markets.

Regulatory & Quality Excellence

Dedicated regulatory, pharmacovigilance and quality teams supporting compliant product commercialisation.

Established Market Access

Strong relationships and infrastructure across key healthcare markets.

Long-Term Partnership Approach

Focused on sustainable growth and shared commercial success.

One Partnership, Multiple Markets

Through Galen and POA Pharma, we provide integrated licensing and commercial capabilities across the UK, Ireland, the Nordics, and wider European markets.

Operating as part of Galen Limited, POA Pharma extends our regional infrastructure and market expertise across key European territories, enabling a coordinated approach to licensing, commercialisation, and lifecycle management.

Founded in 1968 in Northern Ireland, Galen is a privately owned pharmaceutical company with established commercial operations across the UK and Ireland.

We support pharmaceutical products throughout the full commercial lifecycle, from licensing and market entry through to long-term commercial growth and supply management.

Europe & Nordic Regions

Headquartered in Copenhagen, POA Pharma expands our integrated licensing and commercial capabilities across key Nordic and European markets.

Through established regional expertise and commercial infrastructure, POA Pharma supports market access, distribution, and product commercialisation across multiple European territories.

Meet Our Partnership Team

Our Business Development team has extensive experience in pharmaceutical partnerships and is available to discuss licensing and acquisition opportunities.

Johnny McGaughey

Vice President of Business Development

Lisa Hughes

Director – Strategic Projects and Partnerships

Natasha Guy

Business Development Licensing Manager

Aimee Lappin

Business Development Support Manager

Emer Matthews

Business Development Support Coordinator

We are thrilled to be continuing our relationship with Galen through the end of 2027.

They have been our partner for close to 10 years and have successfully built the business across the UK and in Ireland to the point where the UK represents our most important market worldwide outside of Australia.

– Medical Developments International, CEO Brent MacGregor 

Galen has been an outstanding partner for Abiogen in the UK and Ireland, combining deep market expertise with a genuine commitment to patients.

Extending this agreement is a natural next step and reflects our confidence in Galen as the ideal partner to continue our successful collaboration in the years ahead.

– Abiogen Pharma, International Sales Manager Riccardo Fanini

We are proud to collaborate with a trusted international partner to enhance quality of care and improve patients' outcomes

By partnering with Galen, we are strengthening our presence in the Nordic region, ensuring continuity of access and supporting increasingly effective and appropriate management of paediatric patients.

– Istituto Gentili, CEO Alessandro Del Bono

Whether you have a late-stage or ready-to-market pharmaceutical product or asset, or are exploring a strategic acquisition opportunity, our Business Development team would welcome the opportunity to connect.